PeptideDB
de
EnglishEspañolDeutschPortuguês
PeptideKategorienVergleichLeitfädenGlossar

Vesilute

Moderates Forschungsinteresse

ED Dipeptide | Bladder & Urinary Tract Bioregulator

SonstigeLanglebigkeit

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology.

Molekulare und Forschungsdaten

Sequenz
Glu-Asp (ED)
Molekulargewicht
262 Da
Halbwertszeit
Not established
Wege (Forschung)
injectable, oral
Lagerung
Lyophilized powder: room temperature or 2-8°C; Reconstituted: 2-8°C refrigerated, use within 4 weeks

Overview

Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.

Mechanism of action

Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.

Key research findings

  • Supports bladder and urinary tract function
  • May improve prostate health in men
  • Regulates smooth muscle function
  • Enhances pelvic tissue blood flow
  • Supports cellular regeneration
  • Part of comprehensive Khavinson bioregulator protocols
  • Well-tolerated in research
  • Oral bioavailability as small dipeptide

Research applications

Urinary Tract Health

  • Bladder Function Support — Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
  • Urinary Tract Health — May support overall urinary tract function and tissue health.
  • Pelvic Floor Support — Potential benefits for pelvic tissue health and function.

Prostate Health (Men)

  • Prostate Support — Research indicates potential to enhance blood flow and reduce dysfunction in prostate tissue.
  • BPH Symptoms — May help alleviate symptoms associated with benign prostatic hyperplasia.

Anti-Aging Protocol

  • Urogenital Aging — Part of comprehensive bioregulator protocols addressing age-related urogenital changes.
  • Tissue Regeneration — Supports cellular regeneration in urinary and reproductive tissues.

Vesilute Häufig gestellte Fragen

Does Vesilute specifically help with prostate health or only bladder function?+

Vesilute targets both bladder smooth muscle function and prostate health through enhanced blood flow and tissue regeneration. Research indicates potential for relieving BPH (benign prostatic hyperplasia) symptoms, though clinical evidence is limited. The dipeptide's small size allows penetration into prostatic tissue for direct cellular effects.

How is Vesilute different from Prostamax or other prostate-targeting peptides?+

Vesilute (ED dipeptide) is a specific Khavinson bioregulator focusing on bladder and smooth muscle regulation, while Prostamax targets prostate tissue directly. They're complementary - Vesilute works on urinary tract function; Prostamax on prostate inflammation. Combining them may provide comprehensive urogenital support.

Can Vesilute improve urinary symptoms in women?+

While Vesilute is studied primarily in men for prostate support, its bladder smooth muscle regulatory and microcirculation enhancement effects could theoretically benefit women with bladder dysfunction or urinary symptoms. Gender-specific research is limited, but the mechanism suggests potential for both sexes.

How long does Vesilute take to improve urinary flow or BPH symptoms?+

Khavinson bioregulators typically require cycling (10-20 days on, then break) with improvements developing over 2-4 weeks during the first cycle. Maximum benefits emerge after multiple cycles (2-3 per year). Effects persist between cycles due to epigenetic changes, but bioregulator action is gradual compared to pharmaceutical diuretics.

References

  1. [1]Khavinson Bioregulator Peptides: Organ-Specific EffectsSt. Petersburg Institute of Bioregulation and Gerontology
  2. [2]Short Peptides and Urogenital FunctionRussian Medical Research
  3. [3]Bioregulators in Anti-Aging MedicineAdvances in Gerontology

Verwandte Peptide

5-Amino-1MQ

Preclinical

NNMT Inhibitor | Longevity & Metabolic Enhancement

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.

LanglebigkeitMetabolischGewichtsverlust

Adalank

Emerging research

N-Acetyl Selank Amidate | Enhanced Tuftsin Analog

Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.

KognitionLanglebigkeit

Adamax

Emerging research

Next-Generation Semax Derivative | Nootropic Neuropeptide

Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement,

KognitionLanglebigkeit

Cardiogen

Moderate research

AEDR | Cardiovascular Bioregulator Peptide

Cardiogen is a Khavinson bioregulator peptide consisting of four amino acids, derived from heart tissue research.

LanglebigkeitGenesung & Heilung